Conclusion of the OptiSpheres 3 program

Quebec City, July 15, 2021 - Pharma in silica announces the conclusion of the research program OptiSpheres 3.

The development of two original biodistribution assays in mouse models and the development of the second-generation prototype of OpPacli™ (optimized paclitaxel) prototype are among the main results of the program.

The work was carried out in collaboration with SiliCycle chemists and the teams of Professors Nicolas Bertrand and Marc-André Fortin of the CHU de Québec/Université Laval.

About Pharma in silica inc.

Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Since 2019, it has been developing novel treatments for solid cancers (lung, breast, etc.) using OpPacli™, a patented drug nanocarrier. The company is driven by a dynamic group of chemists, pharmacists and managers led by François Arcand, an experienced life sciences entrepreneur (Medicago, Conferences on Plant-made Pharmaceuticals, ERA Biotech). The company established its own research and production facilities and collaborates with oncology experts and world-renowned research centers and has completed the pre-IND/CTA meetings with the FDA and Health Canada.

For more information

François Arcand
President, Pharma in silica inc
514 994 1023 / 418 874-0054 #233
info@pharma-insilica.com

> all news